Caplin Point Laboratories Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/33jifxpvhjb93pl22z8fr6vy.pdf

Key Takeaways


Margin & Profitability Mechanics

C.C. Paarthipan: "It is not the generic that really gives you the money, it is the business model that actually makes you this kind of actually cash flow and profits."

US Business: The Label, The Tariff Risk, The Investment Stance

C.C. Paarthipan: "We will invest in USA the day we understand that our 20% of products gives us the 80% of the business. Then it becomes easy to manufacture only the 20% rather than manufacturing the entire 100%."

LATAM Expansion: Warehouses, Registrations, and the Long Wait

C.C. Paarthipan: "We have registrations to the tune of 400, 500 products, of which 20% will give us the 80% of the revenue. However, the customer who comes here, he may buy one or two products very rarely. He still prefers that product also to be there so that he does not have to go to another warehouse to buy the product."

China Outsourcing: The Second Engine

C.C. Paarthipan: "China has moved from imitation to innovation. Probably, they understood imitation has no limitation, then moved to the innovation."

Product Pipeline: GLP-1, Oncology, Nutraceuticals


Balance Sheet, CAPEX & Capital Allocation

C.C. Paarthipan: "Top line is vanity, bottom line is sanity, and cash is king."

Guidance & Commitments

CommitmentSpecificsTimeline
Contribution margin sustainabilityMaintain at approximately 60%Ongoing
PAT margin sustainabilityMaintain at 26%Ongoing
Caplin Steriles USA launches15 more launchesComing quarters
Nutraceuticals completionEntire process completedNext six months
GLP-1 launch in LATAMLaunch in current LATAM marketsSeptember-October 2026
Mexico warehouseStart warehouse operationsApproximately one year
Mexico product registrations200-250 products registered1.5-2 years
Chile revenue target$50 million businessAfter two years
Long-term growth rate20%-25% double-digit growthAfter three years (post FY28-29)
Cash accrual target₹300 crores per yearYear-on-year
API second-source margin impactMargin contribution from API facilitiesAt least two years away
Brazil officeOpen officeShortly
Mexico factoryStart factoryNext two to three years

Key Metrics

MetricQ1 FY26
Overall revenue₹533 cr, +11.7% YoY
RoW (parent) revenue growth~7% YoY
US business revenue growth37% YoY, on a low base
Contribution margin61.1%, highest thus far, aided by product mix
Gross margin increase+2.1%, flowing through to PAT level
PAT₹151 cr, +20.1% YoY; surpassed FY18 full-year PAT
PAT margin28.1%, up from 26.2% YoY
Cash and cash equivalents₹1,231 cr, part of ₹2,207 cr liquid assets
Caplin Steriles consolidated turnover₹108.48 cr
Caplin Steriles EBITDA₹27.99 cr
Caplin Steriles PAT₹7.95 cr
LATAM market growth7% YoY
US profit contribution₹8 cr of total PAT, rest from LATAM
Caplin Steriles USA ANDAs38 approved, 13 under review
Caplin Steriles USA products launched21 launched, 15 more planned in coming quarters
Inventory positioned near customer56% of total inventory
Realizable revenue from warehouse/transit inventory~₹800 cr
Outsourcing from China30% of total outsourcing
CAPEX invested in last 5 years₹700 cr
CAPEX invested in subsidiaries from parent₹500 cr out of ₹700 cr
Phase-III injectable plant (COL2) CAPEX~₹283 cr, with ₹80–100 cr already spent
Oncology API facility CAPEX~₹85–90 cr
OSD facility CAPEX~₹150 cr expected
Guatemala business$50 million annually
Product registrations in Latin America/Central America400–500, with 20% generating 80% of revenue
Post-registration time to market90–120 days
Regulated market registration timeline15–18 months
US product launch timeline post-approval3–4 months
Mexico private market size vs Central America3x to 4x larger
India generics exports to US$18 bn worth annually
US operating cost vs India5x to 10x higher
Caplin Steriles USA share of total business~5%
FY28 onwards growth expectation20% to 25%
Last three years growth14% to 16%
Year-on-year cash accrual target₹300 cr
Nutraceuticals estimated business in India₹3,000 cr
Peptide cost reductionFrom $500 to $100 per gram
Oncology products under development15–16 products
Products needed for stock-and-sell warehouse model40–50 products
Chile market structure80% tender, 20% private market
Past profit share with US front-end partners50%
US commoditized products gross marginUpwards of 50%